p16INK4a immunocytochemistry in liquid-based cervical cytology: Is it feasible for clinical use?

International Journal of Oncology

Volumn 31, Issue 6, 2007, Pages 1339-1343

  Norman, Ingrid ^a   Brismar, Sophia ^a   Zhu, Jie ^a   Gaberi, Vera ^a   Hagmar, Bjorn ^b   Hjerpe, Anders ^a   Andersson, Sonia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cervical neoplastic lesions; Human papillomavirus; Immunocytochemistry

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 38449119910     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.6.1339     Document Type: Article

References (29)

1. Hemminki K, Li X and Vaittinen P: Time trends in the incidence of cervical and other genital squamous cell carcinomas and adenocarcinomas in Sweden, 1958-1996. Eur J Obstet Gynecol Reprod Biol 101: 64-69, 2002.
2. Sigurdsson K: The Icelandic and Nordic cervical screening programs, trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 78: 478-485, 1999.
3. Cronje HS: Screening for cervical cancer in the developing world. Best Pract Res Clin Obstet Gynaecol 19: 517-529, 2005.
4. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
5. Koutsky LA, Holmes KK, Critchlow CW, et al: A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327: 1272-1278, 1992.
6. Ho GYF, Bierman R, Beardsley L, Chang CJ and Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428, 1998.
7. Elfgren K, Rylander E, Radberg T, et al: Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 193: 650-657, 2005.
8. Gustafsson L, Ponten J, Zack M and Adami O: International incidence rates of invasive cervical cancer after introduction of cyto-logical screening. Cancer Causes Control V8: 755-763, 1997. (Pubitemid 27404646)
9. Creagh T, Bridger JE, Kupek E, Fish DE, Martin-Bates E and Wilkins MJ: Pathologist variation in reporting cervical borderline epithelial abnormalities and cervical intraepithelial neoplasia. J Clin Pathol 48: 59-60, 1995.
10. McCluggage WG, Walsh MY, Thornton CM, et al: Inter- and intra-observer variation in the histopathological reporting of cervical squamous intraepithelial lesions using a modified Bethesda grading system. Br J Obstet Gynaecol 105: 206-210, 1998.
11. Stoler MH, Schiffman M, for the Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study Group: Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285: 1500-1505, 2001.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al: Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 7: 547-555, 2006.
13. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W and Paraskevaidis E: Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies. Gynecol Oncol (In Press).
14. INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92: 276-284, 2001.
15. Martin LG, Demers GW and Galloway DA: Disruption of the G1/S transition in human papillomavirus type 16áE7-expressing human cells is associated with altered regulation of cyclin E. J Virol 72: 975-985, 1998.
16. Hausen HZ: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698, 2000.
17. ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 10: 2407-2414, 2004.
18. Keating JT, Ince T and Crum CP: Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 8: 83-92, 2001.
19. INK4a-positive cells in cervical cytology samples. Acta Cytol 48: 771-782, 2004.
20. Solomon D, Davey D, Kurman R, et al: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119, 2002.
21. INK4a. Int J Oncol 29: 705-711, 2006.
22. INK4a in liquid-based cervicovaginal specimens with modified Papanicolaou counterstaining. J Clin Pathol 59: 827-830, 2006.
23. INK4a- stained cervical squamous cells in liquid-based cytology samples. Cancer 105: 461-467, 2005.
24. INK4a as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep™ smears. J Clin Pathol 56: 56-63, 2003.
25. Carozzi F, Cecchini S, Confortini M, et al: Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. Cancer 108: 119-123, 2006.
26. INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv Anat Pathol 13: 190-194, 2006.
27. Westergaard L and Norgaard M: Severe cervical dysplasia. Control by biopsies or primary conization? A comparative study. Acta Obstet Gynecol Scand 60: 549-554, 1981.
28. Nasiell K, Nasiell M and Vaclavinkova V: Behavior of moderate cervical dysplasia during long-term follow-up. Obstet Gynecol 61: 609-614, 1983.
29. Holowaty P, Miller AB, Rohan T and To T: Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91: 252-258, 1999.